Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 24, 2024 10:00 ET | Source: ConSynance Therapeutics

ConSynance Therapeutics Announces U.S. FDA Grants Rare Pediatric Disease Designation to CSTI-500, a Potential First-in-Class Therapy for Prader-Willi Syndrome

FDA awards ConSynance's CSTI-500 Rare Pediatric Disease Designation for innovative Prader-Willi Syndrome treatment.
November 29, 2023 05:30 ET | Source: Research Nester

Pancreatic Cancer Market revenue to reach USD 36 Billion by 2036, says Research Nester

New York, Nov. 29, 2023 (GLOBE NEWSWIRE) -- The global pancreatic cancer market size is slated to expand at ~18% CAGR between 2024 and 2036. The market is poised to garner a revenue of USD 36...
May 30, 2023 10:00 ET | Source: ConSynance Therapeutics

ConSynance Therapeutics Reports Positive Phase 1 Results for CSTI-500 in Prader-Willi Syndrome Patients

RENSSELAER, New York, May 30, 2023 (GLOBE NEWSWIRE) -- ConSynance Therapeutics, Inc., an emerging biopharmaceutical firm focused on developing novel therapies for rare central nervous system (CNS)...
March 07, 2023 08:00 ET | Source: MBX Biosciences, Inc.

MBX Biosciences to Participate in the Oppenheimer 33rd Annual Healthcare Conference

CARMEL, Ind., March 07, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
January 24, 2023 08:00 ET | Source: MBX Biosciences, Inc.

MBX Biosciences to Participate in the SVB Securities Global Biopharma Conference

CARMEL, Ind., Jan. 24, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
January 05, 2023 08:00 ET | Source: MBX Biosciences, Inc.

MBX Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

CARMEL, Ind., Jan. 05, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
November 14, 2022 08:00 ET | Source: MBX Biosciences, Inc.

MBX Biosciences Closes $115 Million Series B Financing to Advance Development of Endocrine Disease Programs

CARMEL, Ind., Nov. 14, 2022 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
October 05, 2022 09:00 ET | Source: MBX Biosciences, Inc.

MBX Biosciences Advances Phase 1 Clinical Trial of Long-Acting Parathyroid Hormone Peptide Prodrug, MBX 2109

CARMEL, Ind., Oct. 05, 2022 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
July 26, 2022 12:00 ET | Source: MBX Biosciences, Inc.

MBX Biosciences Receives Orphan Drug Designation for Lead Candidate MBX 2109 for the Treatment of Hypoparathyroidism

CARMEL, Ind., July 26, 2022 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing precision endocrine peptide therapeutics to treat endocrine disorders,...
May 24, 2022 10:39 ET | Source: STRATEGIC MARKET RESEARCH LLP

Human Microbiome Market is expected to foster up to a landmark of USD 1318.72 Million by 2030 with a CAGR value of around 31.08%.

New York, United States, May 24, 2022 (GLOBE NEWSWIRE) -- A Human Microbiome comprises archaea, viruses, bacteria, & eukaryotes which reside within & outside our body system. These organisms...

Next Page keyboard_arrow_right